ECE2022 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (202 abstracts)
VLCKD: a real time safety study in obesity
Ludovica Verde 1 , Luigi Barrea 1,2 , Claudia Vetrani 1 , Francesca Marino 1 , Sara Aprano 1 , Silvia Savastano 1 , Annamaria Colao 1 & Giovanna Muscogiuri 1
1Federico II University, Department of Clinical Medicine and Surgery, Endocrinology Unit, Naples, Italy; 2Pegaso Telematic University, Department of Humanities, Naples, Italy
Very Low-Calorie Ketogenic Diet (VLCKD) is currently a promising approach for the treatment of obesity. However, little is known about the side effects since most of the studies reporting them were carried out in normal weight subjects following ketogenic diet for other purposes than obesity. Thus, the aims of the study were: 1) to investigate the safety of VLCKD in subjects with obesity; 2) if VLCKD-related side effects could have an impact on its efficacy. In this prospective study we consecutively enrolled 106 subjects with obesity (12 males and 94 females, BMI 34,98±5,43 kg/m2 ) that underwent to VLCKD. In all subjects we recorded side effects at the end of ketogenic phase and assessed anthropometric parameters at the baseline and at the end of ketogenic phase. In a subgroup of 25 subjects, we also assessed biochemical parameters. Ninety-nine (93,4%) of the subjects enrolled experienced at least one mild side effect but none of the most severe ones. From the most to the less frequent, the percentages of occurrence of the mild side effects were as follows: 49 (46,2%) lethargy, 49 (46,2%) halitosis, 48 (45,3%) headache, 41 (43,5%) dry mouth, 30 (28%) constipation, 19 (17,9%) hypotension, 17 (16%) dizziness, 16 (15,1%) vomiting/nausea, 16 (15,1%) hair loss, 13 (12,3%) diarrhoea, 11 (10,4%) hyperuricemia, 5 (4,7%) visual disturbances, 1 (0,9%) low blood sugar. No one experienced urolithiasis and gallbladder disease. In addition, 9 (8.5%) subjects stopped VLCKD before the end of the protocol for the following reasons: 2 (1.9%) due to palatability and 7 (6,1%) due to excessive costs. Finally, there were no differences in terms of weight loss percentage (13,5±10,9 % vs 18,2±8,9 %; P= 0.318) in subjects that developed side effects and subjects that did not developed side effects. Our study 2 demonstrated that VLCKD is a safe and effective nutritional tool in the management of subject with obesity.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more